JONATHAN SLONIN - 23 May 2022 Form 4 Insider Report for Pacira BioSciences, Inc. (PCRX)

Role: Chief Clinical Officer
Signature: /s/ Kristen Williams, Attorney-in-Fact
Issuer symbol: PCRX
Transactions as of: 23 May 2022
Net transactions value: +$104,740
Form type: 4
Filing time: 25 May 2022, 16:16:23 UTC
Previous filing: 05 Aug 2021
Next filing: 08 Jun 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PCRX	Common Stock	Options Exercise	$104,740	+2,000	+7.5%	$52.37	28,559	23 May 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PCRX	Stock Option (Right to Buy)	Options Exercise	$0	-2,000	-5.3%	$0.000000	35,500	23 May 2022	Common Stock	2,000	$52.37	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes 209 shares of common stock acquired under the issuer's employee stock purchase plan in December 2021.
F2	The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.